<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Protein</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Anti-LAG-3 IL-2 fusion protein enhances ICI and CAR T response in solid tumors</title>
      <description>
        <![CDATA[Although CAR T-cell therapy has been highly effective in hematological cancers, its activity in solid tumors is still constrained by inhibitory checkpoints such as PD-1, LAG-3 and TIM-3, together with the lack of locally available cytokines such as IL-2 needed to sustain T-cell function. Anwita Biosciences Inc. and collaborators aimed to overcome these challenges by developing a strategy integrating an immune checkpoint inhibitor (ICI) with a T-cell stimulatory cytokine.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730696</guid>
      <pubDate>Mon, 27 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730696-anti-lag-3-il-2-fusion-protein-enhances-ici-and-car-t-response-in-solid-tumors</link>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730089</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730089-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Unapproved Anktiva claims earn Immunitybio FDA warning</title>
      <description>
        <![CDATA[Repeated promotional claims Patrick Soon-Shiong made about Immunitybio Inc.’s Anktiva – such as “We have now discovered and developed this drug … approved for bladder cancer, but it actually can treat all cancers” – landed the Culver City, Calif., company a strongly worded warning letter from the U.S. FDA.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729842</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729842-unapproved-anktiva-claims-earn-immunitybio-fda-warning</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Anktiva.webp?t=1713901822" type="image/jpeg" medium="image" fileSize="84741">
        <media:title type="plain">Anktiva </media:title>
        <media:description type="plain">Credit: Business Wire</media:description>
      </media:content>
    </item>
    <item>
      <title>Innovent’s IBI-302 meets phase III endpoints in neovascular AMD </title>
      <description>
        <![CDATA[Innovent Biologics Inc.’s efdamrofusp alfa (IBI-302) met the primary endpoint in the phase III Star trial in neovascular age-related macular degeneration (nAMD), and the Suzhou, China-based company will submit an NDA to China’s National Medical Products Administration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729841</guid>
      <pubDate>Wed, 25 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729841-innovents-ibi-302-meets-phase-iii-endpoints-in-neovascular-amd</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Amsler-grid-test.webp?t=1627064994" type="image/png" medium="image" fileSize="427571">
        <media:title type="plain">Woman taking Amsler grid eye exam</media:title>
      </media:content>
    </item>
    <item>
      <title>Immutep stock plummets 90% on efti phase III failure in NSCLC</title>
      <description>
        <![CDATA[Immutep Ltd.’s stock on Australia’s Securities Exchange plummeted nearly 90% on March 13 on the news that its phase III TACTI-004 trial evaluating eftilagimod alfa (IMP-321, efti) in first-line non-small-cell lung cancer was discontinued due to futility.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729716</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729716-immutep-stock-plummets-90-on-efti-phase-iii-failure-in-nsclc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Stock-crash-arrow.webp?t=1588792244" type="image/png" medium="image" fileSize="573421">
        <media:title type="plain">Stock market crash illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Immutep stock plummets 90% on efti phase III failure in NSCLC</title>
      <description>
        <![CDATA[Immutep Ltd.’s stock on Australia’s Securities Exchange plummeted nearly 90% on March 13 on the news that its phase III TACTI-004 trial evaluating eftilagimod alfa (IMP-321, efti) in first-line non-small-cell lung cancer was discontinued due to futility.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729493</guid>
      <pubDate>Fri, 13 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729493-immutep-stock-plummets-90-on-efti-phase-iii-failure-in-nsclc</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Stock-crash-arrow.webp?t=1588792244" type="image/png" medium="image" fileSize="573421">
        <media:title type="plain">Stock market crash illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Vertex filing BLA for ‘best-in-class’ IgAN drug on Rainier win</title>
      <description>
        <![CDATA[Vertex Pharmaceuticals Inc. is on track to complete a BLA by the end of March seeking potential U.S. accelerated approval for povetacicept, its dual inhibitor of the BAFF and APRIL cytokines, to treat immunoglobulin A nephropathy (IgAN), following a successful phase III Rainier trial.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729449</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729449-vertex-filing-bla-for-best-in-class-igan-drug-on-rainier-win</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/Kidneys.webp?t=1585681893" type="image/png" medium="image" fileSize="393213">
        <media:title type="plain">Kidneys</media:title>
      </media:content>
    </item>
    <item>
      <title>Returning to pulmonary hypertension, GSK buys 35Pharma </title>
      <description>
        <![CDATA[GSK plc is paying $950 million cash to acquire 100% of 35Pharma Inc.’s equity and pipeline, including phase II-ready candidate HS-235 for pulmonary hypertension. The acquisition agreement comes a day after GSK added two small interfering RNA assets from Nanjing, China-based Frontier Biotechnologies Inc. through a license deal reaching up to $1 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729368</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729368-returning-to-pulmonary-hypertension-gsk-buys-35pharma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-heart-anatomy.webp?t=1772042014" type="image/jpeg" medium="image" fileSize="519932">
        <media:title type="plain">Lungs, heart anatomy </media:title>
      </media:content>
    </item>
    <item>
      <title>Ninth Circuit agrees with Lilly in royalty dispute </title>
      <description>
        <![CDATA[Eli Lilly and Co. got a breather when the U.S. Ninth Circuit Court of Appeals agreed that the company doesn’t owe Research Corporation Technologies Inc. (RCT) royalties on its diabetes drugs under a licensing agreement Lilly had made with Phillips Petroleum Co. in 1990 and that Phillips later sold to RCT.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729246</guid>
      <pubDate>Thu, 26 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729246-ninth-circuit-agrees-with-lilly-in-royalty-dispute</link>
    </item>
    <item>
      <title>Vivtex’s oral drug delivery approach draws Novo in $2.1B deal</title>
      <description>
        <![CDATA[Coming off a U.S. FDA approval of the first GLP-1 in pill format, Novo Nordisk A/S leaned further into oral drug delivery efforts, partnering with Vivtex Corp. to develop next-generation oral formulations of peptide and protein therapeutics in a potential $2.1 billion deal that marks the highest-profile news for Vivtex since the firm spun out of MIT in 2018.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729200</guid>
      <pubDate>Wed, 25 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729200-vivtexs-oral-drug-delivery-approach-draws-novo-in-21b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/GI-ORIS-pic-Vivtex-2-25.webp?t=1772058346" type="image/jpeg" medium="image" fileSize="528373">
        <media:title type="plain">GI-ORIS-pic-Vivtex-2-25.jpg</media:title>
        <media:description type="plain">GI-ORIS, or “GI tract on a chip” screening system.
Credit: Vivtex Corp.</media:description>
      </media:content>
    </item>
    <item>
      <title>Returning to pulmonary hypertension, GSK buys 35Pharma </title>
      <description>
        <![CDATA[GSK plc is paying $950 million cash to acquire 100% of 35Pharma Inc.’s equity and pipeline, including phase II-ready candidate HS-235 for pulmonary hypertension. The acquisition agreement comes a day after GSK added two small interfering RNA assets from Nanjing, China-based Frontier Biotechnologies Inc. through a license deal reaching up to $1 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729199</guid>
      <pubDate>Wed, 25 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729199-returning-to-pulmonary-hypertension-gsk-buys-35pharma</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Respiratory/Lungs-heart-anatomy.webp?t=1772042014" type="image/jpeg" medium="image" fileSize="519932">
        <media:title type="plain">Lungs, heart anatomy </media:title>
      </media:content>
    </item>
    <item>
      <title>Evommune, Nektar soar on atopic dermatitis phase II data</title>
      <description>
        <![CDATA[Marking an important day for those with atopic dermatitis, shares of two biopharmas surged on clinical data suggesting new biologics are on their way to help address 40% of patients with uncontrolled disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728714</guid>
      <pubDate>Tue, 10 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728714-evommune-nektar-soar-on-atopic-dermatitis-phase-ii-data</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Dermatologic/Woman-itching-wrist.webp?t=1666388233" type="image/png" medium="image" fileSize="402547">
        <media:title type="plain">Woman itching wrist</media:title>
      </media:content>
    </item>
    <item>
      <title>AI meets antibody design: Galux draws $29M series B for drug R&amp;D</title>
      <description>
        <![CDATA[Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/728806</guid>
      <pubDate>Tue, 10 Feb 2026 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728806-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Park-Tae-yong-vice-president-and-cofounder-Galux-2-9.webp?t=1770669296" type="image/jpeg" medium="image" fileSize="481724">
        <media:title type="plain">Park Tae-yong, vice president and cofounder, Galux</media:title>
        <media:description type="plain">Park Tae-yong, vice president and cofounder, Galux Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>AI meets antibody design: Galux draws $29M series B for drug R&amp;D</title>
      <description>
        <![CDATA[Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728800</guid>
      <pubDate>Tue, 10 Feb 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728800-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Park-Tae-yong-vice-president-and-cofounder-Galux-2-9.webp?t=1770669296" type="image/jpeg" medium="image" fileSize="481724">
        <media:title type="plain">Park Tae-yong, vice president and cofounder, Galux</media:title>
        <media:description type="plain">Park Tae-yong, vice president and cofounder, Galux Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>AI meets antibody design: Galux draws $29M series B for drug R&amp;D</title>
      <description>
        <![CDATA[Galux closed a ₩42 billion (US$29 million) series B round Feb. 10, led by Yuanta Investment to bring AI-driven “rational design” to the protein drug development process, already heavily influenced by human engineering.&nbsp;]]>
      </description>
      <guid>http://www.bioworld.com/articles/728701</guid>
      <pubDate>Mon, 09 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728701-ai-meets-antibody-design-galux-draws-29m-series-b-for-drug-r-and-d</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Park-Tae-yong-vice-president-and-cofounder-Galux-2-9.webp?t=1770669296" type="image/jpeg" medium="image" fileSize="481724">
        <media:title type="plain">Park Tae-yong, vice president and cofounder, Galux</media:title>
        <media:description type="plain">Park Tae-yong, vice president and cofounder, Galux Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>First-in-class fusion protein reverses T-cell exhaustion across multiple models</title>
      <description>
        <![CDATA[IL-10-based approaches have shown promise in cancer immunotherapy by activating exhausted CD8+ T cells, but severe hematological toxicities have limited their clinical use. Recent strategies aim to harness IL-10’s antitumor effects while reducing these toxicities.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728604</guid>
      <pubDate>Wed, 04 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728604-first-in-class-fusion-protein-reverses-t-cell-exhaustion-across-multiple-models</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Tcell-lymphocyte.webp?t=1733935042" type="image/jpeg" medium="image" fileSize="367584">
        <media:title type="plain">Illustration of a T cell</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA clears clinical trial of Henlius’ HLX-701</title>
      <description>
        <![CDATA[China’s National Medical Products Administration (NMPA) has cleared Shanghai Henlius Biotech Inc. to initiate a phase Ib/II trial of HLX-701 in combination with cetuximab and chemotherapy for the treatment of patients with advanced RAS/BRAF wild-type colorectal cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728207</guid>
      <pubDate>Thu, 22 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728207-chinas-nmpa-clears-clinical-trial-of-henlius-hlx-701</link>
    </item>
    <item>
      <title>Rage Bio enters clinic with inhaled oligonucleotide in COPD</title>
      <description>
        <![CDATA[After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its lead candidate, RB-042, an inhaled splice-switching oligonucleotide for treating chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728046</guid>
      <pubDate>Wed, 14 Jan 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728046-rage-bio-enters-clinic-with-inhaled-oligonucleotide-in-copd</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Respiratory-lungs-inflammation.webp?t=1698075497" type="image/jpeg" medium="image" fileSize="261810">
        <media:title type="plain">AI generated illustration of lungs in the human body</media:title>
      </media:content>
    </item>
    <item>
      <title>Rage Bio enters clinic with inhaled oligonucleotide in COPD</title>
      <description>
        <![CDATA[After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its lead candidate, RB-042, an inhaled splice-switching oligonucleotide for treating chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727978</guid>
      <pubDate>Tue, 13 Jan 2026 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727978-rage-bio-enters-clinic-with-inhaled-oligonucleotide-in-copd</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Respiratory-lungs-inflammation.webp?t=1698075497" type="image/jpeg" medium="image" fileSize="261810">
        <media:title type="plain">AI generated illustration of lungs in the human body</media:title>
      </media:content>
    </item>
    <item>
      <title>Rage Bio enters clinic with inhaled oligonucleotide in COPD</title>
      <description>
        <![CDATA[After raising AU$29 million (US$19.44 million) in a series A round, Rage Biotech Pty Ltd. is beginning phase I trials of its lead candidate, RB-042, an inhaled splice-switching oligonucleotide for treating chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727869</guid>
      <pubDate>Mon, 12 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727869-rage-bio-enters-clinic-with-inhaled-oligonucleotide-in-copd</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Respiratory-lungs-inflammation.webp?t=1698075497" type="image/jpeg" medium="image" fileSize="261810">
        <media:title type="plain">AI generated illustration of lungs in the human body</media:title>
      </media:content>
    </item>
    <item>
      <title>Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery</title>
      <description>
        <![CDATA[Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital alchemy,’” Kim told <em>BioWorld</em>, describing how AI is shifting some drug discovery processes from physical to virtual spaces.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727277</guid>
      <pubDate>Wed, 17 Dec 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727277-hits-hyperlab-launches-as-virtual-ai-lab-for-new-drug-discovery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Kim-Woo-youn-CEO-and-cofounder-Hits-12-15.webp?t=1765911302" type="image/jpeg" medium="image" fileSize="675292">
        <media:title type="plain">Kim Woo-youn, CEO and cofounder, Hits</media:title>
        <media:description type="plain">Kim Woo-youn, CEO and cofounder, Hits</media:description>
      </media:content>
    </item>
    <item>
      <title>Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery</title>
      <description>
        <![CDATA[Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital alchemy,’” Kim told <em>BioWorld</em>, describing how AI is shifting some drug discovery processes from physical to virtual spaces.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727003</guid>
      <pubDate>Tue, 16 Dec 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727003-hits-hyperlab-launches-as-virtual-ai-lab-for-new-drug-discovery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Kim-Woo-youn-CEO-and-cofounder-Hits-12-15.webp?t=1765911302" type="image/jpeg" medium="image" fileSize="675292">
        <media:title type="plain">Kim Woo-youn, CEO and cofounder, Hits</media:title>
        <media:description type="plain">Kim Woo-youn, CEO and cofounder, Hits</media:description>
      </media:content>
    </item>
    <item>
      <title>GSK-Flagship deal validates Profound, Quotient platforms</title>
      <description>
        <![CDATA[Two Flagship Pioneering Inc. biopharma companies founded in the last five years and focused on proteomic and genomic technologies entered agreements to help discover new therapeutics for respiratory and liver diseases under a framework collaboration with GSK plc. Under that agreement, Profound Therapeutics Inc. and Quotient Therapeutics Inc. would use their platform technologies to discover novel proteins and targets for developing drugs to treat chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis, with Quotient taking on a third indication with metabolic dysfunction-associated steatohepatitis.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726321</guid>
      <pubDate>Thu, 20 Nov 2025 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726321-gsk-flagship-deal-validates-profound-quotient-platforms</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Hands-and-gears.webp?t=1590606316" type="image/png" medium="image" fileSize="377385">
        <media:title type="plain">Hands holding gears</media:title>
      </media:content>
    </item>
    <item>
      <title>Series A financing at AI Proteins to advance de novo miniproteins</title>
      <description>
        <![CDATA[AI Proteins Inc. has closed a $41.5 million series A financing round to accelerate AI-driven design and development of purpose-built miniprotein medicines across therapeutic applications.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726358</guid>
      <pubDate>Thu, 20 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726358-series-a-financing-at-ai-proteins-to-advance-de-novo-miniproteins</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/finance-dollar-growth.webp?t=1638226495" type="image/png" medium="image" fileSize="416016">
        <media:title type="plain">Hand holding dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Celltrion signs $744M deal with Kaigene, $500M with Mustbio</title>
      <description>
        <![CDATA[Celltrion Inc. scored a hat-trick of deals to license new antibody candidates, including a $744 million deal with Kaigene Inc. Nov. 3, and a near $500 million deal with Mustbio Co. Ltd. Oct. 31.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726151</guid>
      <pubDate>Tue, 11 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726151-celltrion-signs-744m-deal-with-kaigene-500m-with-mustbio</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Celltrion-signage.webp?t=1692390081" type="image/jpeg" medium="image" fileSize="272106">
        <media:title type="plain">Celltrion building and skyline</media:title>
        <media:description type="plain">Credit: Celltrion Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Celltrion signs $744M deal with Kaigene, $500M with Mustbio</title>
      <description>
        <![CDATA[Celltrion Inc. scored a hat-trick of deals to license new antibody candidates, including a $744 million deal with Kaigene Inc. Nov. 3, and a near $500 million deal with Mustbio Co. Ltd. Oct. 31.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725803</guid>
      <pubDate>Wed, 05 Nov 2025 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/725803-celltrion-signs-744m-deal-with-kaigene-500m-with-mustbio</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/Celltrion-signage.webp?t=1692390081" type="image/jpeg" medium="image" fileSize="272106">
        <media:title type="plain">Celltrion building and skyline</media:title>
        <media:description type="plain">Credit: Celltrion Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Levicept data show neurotrophin inhibitor may be disease modifying in osteoarthritis</title>
      <description>
        <![CDATA[An examination of X-ray and MRI scans of 518 patients before and after treatment with Levicept Ltd.’s Levi-04 has shown that, in addition to providing significant analgesia, the selective neurotrophin-3 inhibitor may have a disease-modifying effect in osteoarthritis of the knee.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725578</guid>
      <pubDate>Tue, 28 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725578-levicept-data-show-neurotrophin-inhibitor-may-be-disease-modifying-in-osteoarthritis</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Inflammation-osteoarthritis-knee-pain.webp?t=1679672539" type="image/png" medium="image" fileSize="1333071">
        <media:title type="plain">Illustration of leg anatomy with target around knee</media:title>
      </media:content>
    </item>
    <item>
      <title>Leads Biolabs joins a $1B development deal with Dianthus</title>
      <description>
        <![CDATA[Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The company will pay as much as $1 billion to Nanjing Leads Biolabs Co. Ltd. for DNTH-212, a bifunctional BDCA2 and BAFF/APRIL inhibitor to treat autoimmune disorders. The payment comprises $30 million up front and some near-term milestones, plus an $8 million milestone for getting a phase I study underway. Leads Biolabs is in line to bring in another $962 million in milestones and royalties.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725428</guid>
      <pubDate>Tue, 21 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725428-leads-biolabs-joins-a-1b-development-deal-with-dianthus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deals-handshake-analysis-illustration.webp?t=1614643337" type="image/png" medium="image" fileSize="1213840">
        <media:title type="plain">Concept of business partnership</media:title>
      </media:content>
    </item>
    <item>
      <title>Leads Biolabs joins a $1B development deal with Dianthus</title>
      <description>
        <![CDATA[Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The company will pay as much as $1 billion to Nanjing Leads Biolabs Co. Ltd. for DNTH-212, a bifunctional BDCA2 and BAFF/APRIL inhibitor to treat autoimmune disorders. The payment comprises $30 million up front and some near-term milestones, plus an $8 million milestone for getting a phase I study underway. Leads Biolabs is in line to bring in another $962 million in milestones and royalties.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725360</guid>
      <pubDate>Mon, 20 Oct 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725360-leads-biolabs-joins-a-1b-development-deal-with-dianthus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deals-handshake-analysis-illustration.webp?t=1614643337" type="image/png" medium="image" fileSize="1213840">
        <media:title type="plain">Concept of business partnership</media:title>
      </media:content>
    </item>
    <item>
      <title>Leads Biolabs joins a $1B development deal with Dianthus</title>
      <description>
        <![CDATA[Dianthus Therapeutics Inc. has joined the recent trend of companies licensing therapies in development from China. The company will pay as much as $1 billion to Nanjing Leads Biolabs Co. Ltd. for DNTH-212, a bifunctional BDCA2 and BAFF/APRIL inhibitor to treat autoimmune disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725218</guid>
      <pubDate>Thu, 16 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725218-leads-biolabs-joins-a-1b-development-deal-with-dianthus</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deals-handshake-analysis-illustration.webp?t=1614643337" type="image/png" medium="image" fileSize="1213840">
        <media:title type="plain">Concept of business partnership</media:title>
      </media:content>
    </item>
  </channel>
</rss>
